Diarrhea

Probiotics Show No Benefits for Pediatric Acute Gastroenteritis

November 26, 2018

No benefits seen with Lactobacillus rhamnosus GG or L. rhamnosus R0011 and L. helveticus R0052

FDA Approves New Treatment for Travelers' Diarrhea

By November 19, 2018

Aemcolo is a broad spectrum, semi-synthetic, orally-administered, minimally-absorbed antibiotic designed to allow for delayed release to the colon.

FDA to Review Aemcolo for Treatment of Travelers' Diarrhea

By May 23, 2018

A Phase 3 clinical trial of patients with travelers' diarrhea demonstrated that Aemcolo was superior to placebo (P=.0008) and non-inferior to ciprofloxacin.

Firvanq Availability Replaces Need for Compounded Oral Vancomycin Solution

By April 02, 2018

Firvanq will replace CutisPharma's FIRST-Vancomycin Unit-of-Use Compounding Kit.

Efficacy of Linaclotide, Plecanatide Evaluated for CIC, IBS-C Treatment

By January 31, 2018

There was no significant difference between the two therapies in odds ratios for efficacy, diarrhea, or diarrhea-related study withdrawals.

FDA to Limit Amount of Doses in OTC Antidiarrheal Packages

By January 30, 2018

The FDA will be working with manufacturers to use blister packs or other single-dose packaging in efforts to limit the number of doses in a package.

Diarrhea Med Recalled Due to Potential for Super or Sub Potent Tablets

By November 17, 2017

Diphenoxylate hydrochloride and atropine sulfate tablets are indicated as adjunctive therapy in the management of diarrhea in patients 13 years of age and older.

Aemcolo Gets QIDP, Fast Track Designation for Travelers' Diarrhea

By October 31, 2017

In Phase 3 clinical trials involving patients with travelers' diarrhea, Aemcolo was found to be superior to placebo (P=0.0008) and non-inferior to ciprofloxacin.

IDSA: New Clinical Practice Guidelines on Infectious Diarrhea Management

By October 19, 2017

The expert panel states that for the majority of patients with diarrhea, diagnostic testing is unnecessary.

Cases of Cyclosporiasis on the Rise, CDC Warns

By August 08, 2017

A total of 206 cases of Cyclospora infections have been reported to the CDC as of August 2, 2017 among individuals who became ill on or after May 1, 2017.

Clinically Meaningful Reductions in HIV-Related Diarrhea with Long-Term Crofelemer

By July 27, 2017

Data from the analysis showed a 73% mean reduction in diarrhea episodes from baseline after treatment with Mytesi for 24 weeks.

CDC: Cryptosporidiosis Outbreaks Up at Aquatic Facilities

May 19, 2017

Ohio experienced a nearly 5-fold increase in cryptosporidiosis cases in 2016, with 1,940 reported cases compared with an average 399 cases during the prior 4 years.

First-in-Class Oral Enzyme Designated Breakthrough Therapy for CDI Prevention

By May 11, 2017

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for ribaxamase (SYN-004; Synthetic Biologics) for the prevention of Clostridium difficile infection (CDI).

How Common are Adverse GI Events with Statin Therapy?

By April 17, 2017

The analyses found no statistically significant difference between statin use and lower gastrointetinal conditions in constipation (OR 0.96, 95% CI: 0.87-1.05; P=0.33), abdominal pain (OR 0.95, 95% CI: 0.88-1.02; P=0.15), or colitis (OR 1.02, 95% CI: 0.91-1.14; P=0.73).

Xermelo Approved for Carcinoid Syndrome Diarrhea

By March 01, 2017

That FDA has approved Xermelo (telotristat ethyl) tablets as the first oral treatment for carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.

Drugs Often Overlooked as a Cause of Chronic Diarrhea

By February 09, 2017

Over 700 drugs have been associated with causing diarrhea.

Amneal Launches Generic Lotronex

By January 31, 2017

Amneal has launched Alosetron HCl Tablets, the generic equivalent to Prometheus' Lotronex.

<i>Clostridium difficile</i> Antibody Efficacy Examined in Real World Setting

January 26, 2017

Bezlotoxumab (Zinplava) is effective in reducing the risk of recurrent Clostridium difficile infection, according to research published in the New England Journal of Medicine.

Antidiarrheal May Be Increasing in Popularity as Drug of Abuse

By January 24, 2017

Clinicians should consider performing a screening electrocardiogram for patients who present after acute or chronic high-dose ingestion.

Is Bezlotoxumab Efficacy Affected by Concomitant Antibiotics for <i>C. diff</i>?

By October 27, 2016

Patients given bezlotoxumab exhibited significantly less Clostridium difficile infection (CDI) recurrence regardless of choice of standard of care (SoC) antibiotics, according to a study presented at IDWeek.

FDA Approves Zinplava to Prevent <i>C. diff</i> Infection Recurrence

By October 24, 2016

Zinplava is a human monoclonal IgG1/kappa antibody.

Mytesi Available to Treat Noninfectious Diarrhea in HIV Patients

By October 13, 2016

Crofelemer is a botanical drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest.

Antidepressant Efficacy Evaluated in Pediatric Abdominal Pain

By September 28, 2016

The review included children aged 5-21 years with functional abdominal pain treated with SSRI or TCA.

The Ins and Outs of Inulin, a Food with Function

September 20, 2016

Inulin exerts substantial prebiotic actions.

Oral Antibacterial Granted QIDP Status for C. Difficile-Associated Diarrhea

By September 12, 2016

The FDA has granted MGB-BP-3 (MGB Biopharma) Qualified Infectious Disease Product (QIDP) designation for the treatment of Clostridium difficile-associated diarrhea (CDAD).

New Warning, Administration Info Added to Labeling for OIC Drug Movantik

By August 24, 2016

The Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Movantik (naloxegol; AstraZeneca) tablets.

How Often is Fidaxomicin Used for <i>C. difficile</i> Infection?

By August 19, 2016

A slow but consistent increase in fidaxomicin use has been seen over time for the treatment of Clostridium difficile infection mostly in combination with other systemic antibiotics, study authors reported in Springer Plus.

Review: Management of Persistent Diarrhea

July 07, 2016

Microbiological causes of protracted diarrhea include detectable parasitic and bacterial pathogens

Zinplava Gets FDA Committee Nod for Prevention of CDI Recurrence

By June 10, 2016

Merck announced that the Antimicrobial Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 10-5 recommending the approval of Zinplava (bezlotoxumab) for the prevention of Clostridium difficile (C. difficile) infection recurrence.

FDA: Serious Heart Problems Possible with High Doses of Antidiarrheal

By June 07, 2016

The most severe cases involved doses ranging from 70mg-1600mg daily, which is 4-100 times the recommended dose.